AI Consensus Investment Thesis
RxSight (RXST) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
No Action - Keep Monitoring
Only one horizon is positive; wait for broader confirmation.
1-Year
NEUTRAL$7.19
+2.2%5-Year
BUY$20
+189.0%Latest flagship insight
Why This High-Margin Medical Technology Asset Is Trading Below Book Value
There is high consensus that this medical technology asset presents a profound valuation anomaly, trading below book value despite elite gross margins. While a cyclical capital equipment freeze pressures near-term placements, the compounding installed base of post-operative adjustable lenses provides a highly resilient, recurring revenue stream.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The asset represents a structural paradigm shift in premium ophthalmology, currently mispriced due to a cyclical capital equipment capexcapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry freeze. While high interest rates and stagflationary pressuresstagflationary pressuresEconomic pressures created when weak growth and persistent inflation occur together.View full glossary entry temporarily stall hardware placements, the underlying unit economicsunit economicsRevenue, variable cost, contribution profit, and acquisition or retention economics measured for one customer, product, transaction, or operating unit.View full glossary entry remain exceptional, characterized by gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry exceeding seventy-five percent. The core investment thesis centers on the transition from capital-intensive hardware sales to a highly profitable, recurring consumables model driven by an expanding installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry of light delivery devices. This transition creates a powerful operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry coiled spring that will trigger as macro headwindsmacro headwindsBroad economic conditions that can slow growth, weaken demand, or pressure asset valuations.View full glossary entry subside.
Key insights
- Core intellectual propertyintellectual propertyLegally protected intangible creations such as patents, copyrights, trademarks, designs, trade secrets, and proprietary know-how.View full glossary entry on post-operative adjustability secures a localized monopoly and intense pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry.
- Pristine balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry with a current ratio over ten and negligible debt provides an impenetrable liquidation floorliquidation floorA downside value estimate based on what assets could realize in a forced sale scenario.View full glossary entry.
- Cyclical capital equipment sales contraction is mispriced as a permanent structural impairmentstructural impairmentLasting damage to earning power, competitive position, asset value, or business-model viability.View full glossary entry of the business model.
- High-margin consumable lens volume compounds as the existing installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry increases clinical throughput.
- Significant strategic M&A optionality exists as the enterprise valueenterprise valueA measure of total business value, commonly calculated as equity value plus debt and preferred claims, less cash and cash equivalents.View full glossary entry approaches zero, making it an attractive bolt-on target.
- Major risks include prolonged consumer stagflationconsumer stagflationEconomic state of stagnant growth combined with high inflation impacting consumer purchasing power.View full glossary entry squeezing out-of-pocket premium upgrades and potential regulatory reimbursement shifts.
- Operational efficiencyoperational efficiencyThe ability to produce an intended output or service with minimal waste, delay, or cost.View full glossary entry gains from right-sizing bloated sales and marketing expenses will accelerate the path to positive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The conventional market narrative views the asset as a broken growth story and a toxic value trapvalue trapA stock that appears cheap based on valuation metrics but remains stagnant due to fundamental business deterioration.View full glossary entry. Analysts and retail investors are heavily focused on the recent double-digit revenue contraction and the steep collapse in capital equipment sales, attributing these issues to a permanent failure of product-market fit. The crowd believes that in a high-interest-rate, stagflationary environmentstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry, clinics will indefinitely freeze equipment purchases and seniors will reject premium out-of-pocket upgrades. Furthermore, the market treats pending securities class-action lawsuits as an existential threat, ignoring the underlying technology and the massive cash cushion on the balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's failure to distinguish between a temporary cyclical pause in capital spending and a permanent structural impairmentstructural impairmentLasting damage to earning power, competitive position, asset value, or business-model viability.View full glossary entry of the business. While the crowd panic-sells the drop in low-margin hardware placements, they overlook the compounding value of the installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry. This base acts as a captive network generating recurring, seventy-six percent gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry consumable lens sales, which continue to grow. Furthermore, the market is pricing the enterprise valueenterprise valueA measure of total business value, commonly calculated as equity value plus debt and preferred claims, less cash and cash equivalents.View full glossary entry near zero, ignoring that the company holds cash and equity that exceed its entire market capitalizationmarket capitalizationThe market value of an asset or company, commonly calculated for a company as share price multiplied by shares outstanding.View full glossary entry. The variant perceptionvariant perceptionAn investment view that differs from market consensus and assumes future outcomes will be better or worse than widely expected.View full glossary entry recognizes that biological healing is unpredictable, making post-operative physical adjustment a thermodynamic necessity that software or pre-operative measurements cannot replicate, securing a durable monopoly.
Repricing Catalyst
What could make the market recognize and close that gap? The primary catalyst to force a market repricing is the demonstration of sequential top-line stabilization and positive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry crossover, proving the recent downturn was a cyclical anomaly. This inflection, expected within twelve to eighteen months, will be driven by compounding consumable lens utilization overriding the hardware sales drag. Additionally, public disclosure of activist investor involvement demanding operating expense rationalization, or a formal strategic buyout offer from a major medical technology incumbent, would instantly close the valuation gapvaluation gapThe difference between a market price and an analyst's estimate of intrinsic value.View full glossary entry and force the market to recognize the asset's true intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Extreme Fear
- Volatility
- High Erratic
- Cycle position
- Capitulation
While there is strong consensus that the asset is currently in a capitulation phase characterized by extreme fear and high volatility, minor disagreements exist regarding the speed of stabilization. Some perspectives suggest a near-term reversal driven by immediate cost-cutting, while others expect a prolonged consolidation period before macro headwindsmacro headwindsBroad economic conditions that can slow growth, weaken demand, or pressure asset valuations.View full glossary entry subside.
Macro Regime Fit
Does the current market environment support the thesis? The current macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of energy-driven stagflationstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry and restrictive monetary policy presents a severe near-term headwind. Elevated interest rates restrict capital equipment financing for clinics, while persistent inflation compresses the discretionary out-of-pocket spending capacity of the target senior demographic. However, the company's exceptional liquidity profile and zero-debt structure insulate it from credit-refinancing risks that threaten leveraged competitors. Over the long term, the structural demographic tailwind of an aging global population provides an unyielding, non-discretionary baseline of cataract surgeries, ensuring the asset's survival and eventual recovery as macro pressures ease.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across reports centers on the expected duration of the capital equipment sales freeze and the urgency of cost-cutting. Some perspectives assume a rapid recovery in machine placements by mid-2027 as interest rates stabilize, while others model a structural, multi-year freeze that forces a permanent transition to a pure consumables harvest model. Additionally, there is divergence regarding management's capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry; some views heavily criticize the current operating expense burn as destructive, while others prioritize maintaining commercial footprint investments to defend the technological moattechnological moatA durable competitive advantage created by proprietary technology, know-how, data, patents, engineering capability, or technical scale.View full glossary entry against oligopolistic competitors.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Monopoly Moat in Post-Operative Adjustability | Innovation And Product | +150% | +120% | The proprietary Light Adjustable Lens holds a unique FDA approval, allowing post-surgical UV-light fine-tuning to correct refractive surprises. This technological monopoly protects pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry on the consumable side, insulating the seventy-seven percent gross margin profilegross margin profileThe level, composition, durability, and variability of gross margin across a business or product mix.View full glossary entry against standard cataract market commoditizationcommoditizationThe process where services become indistinguishable, leading to price-based competition and severe margin erosion.View full glossary entry. Because biological healing is unpredictable, this post-operative adjustment remains a clinical necessity, forcing surgeons to remain tethered to the ecosystem. |
| Fortress Balance Sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry and Liquidity Floor | Capital Allocation | +80% | +15% | With a current ratio exceeding ten, negligible debt, and cash reserves that nearly match or exceed the entire market capitalizationmarket capitalizationThe market value of an asset or company, commonly calculated for a company as share price multiplied by shares outstanding.View full glossary entry, the company possesses an indestructible capital fortress. This extreme liquidity eliminates refinancing risks during tight monetary cycles and provides a decade of operational runway, guaranteeing survival and preventing dilutive financing while competitors struggle. |
| High-Margin Consumables Transition | Operational Efficiency | +70% | +90% | The embedded installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry of over eleven hundred machines generates recurring, high-margin consumable lens sales. As the revenue mix shifts away from cyclical capital equipment sales toward these recurring consumables, the gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry expands structurally. This transition creates massive latent operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry, ensuring that any incremental volume recovery flows directly to the bottom line. |
| Structural Demographic Cataract Volume | Sector And Industry | +45% | +35% | The aging global population guarantees a compounding, non-discretionary baseline of cataract surgeries that cannot be delayed indefinitely. While premium out-of-pocket upgrades face short-term cyclical pressure, the underlying procedure volume provides a durable patient funnel. This demographic tailwind acts as a perpetual volume floor, ensuring long-term expansion of the addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Clinical Capital Equipment Sales Freeze | Macroeconomic And Macrofinancial | -45% | -55% | The restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry and elevated interest rates have frozen clinical capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry budgets. Ophthalmology practices are deferring expensive hardware purchases, causing a severe collapse in new machine placements. This capital freeze chokes the distribution funnel, delaying the expansion of the installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry and limiting the near-term growth of high-margin consumables. |
| StagflationarystagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry Consumer Discretionaryconsumer discretionarySector classification for non-essential goods sensitive to macroeconomic cycles and consumer spending power.View full glossary entry Squeeze | Macroeconomic And Macrofinancial | -35% | -40% | Persistent inflation and declining real incomes compress the discretionary spendingdiscretionary spendingConsumer expenditure on non-essential goods sensitive to economic downturns and inflation.View full glossary entry power of the target senior demographic. Because the adjustable lens requires significant out-of-pocket premium payments, financially stressed patients are down-trading to standard, fully covered alternatives. This consumer squeeze acts as a structural ceiling on premium upgrade rates and near-term volume growth. |
| Bloated Operating Expense Cash Burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry | Capital Allocation | -30% | -45% | Management's reluctance to align operating expenses with the new, low-growth reality has resulted in a high cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry rate. Continuing to fund a bloated sales and marketing apparatus designed for a low-rate environment creates negative operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry. This persistent burn erodes the protective cash cushion and delays the transition to positive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. |
| Securities Fraud Class-Action Overhang | Management And Governance | -20% | -10% | Pending securities fraud class-action lawsuits alleging misrepresented utilization metrics cast a shadow over management's credibility. Defending these suits drains executive bandwidth and cash reserves while repelling institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry. Until resolved, this legal overhang enforces a structural valuation discount on the equity, overshadowing fundamental improvements. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Unchecked Cash Burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry and DilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry | 30% | -55% | Capital Allocation | If management stubbornly maintains high operational spending despite a prolonged macroeconomic downturn, the pristine cash reserves could evaporate within a few years. This unchecked cash incineration would destroy the balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry's protective floor, forcing a highly dilutive equity raisedilutive equity raiseAn equity financing that increases shares outstanding and reduces existing owners' percentage ownership.View full glossary entry at distressed valuations and permanently impairing shareholder value. |
| AI-Driven Pre-Operative Simulation Breakthrough | 15% | -70% | Innovation And Product | A competitor leverages advanced artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry and imaging to perfectly predict post-healing corneal geometry before surgery. If pre-operative calculations achieve near-perfect accuracy, the clinical need for post-operative physical light adjustments would be entirely negated, rendering the company's core technology obsolete. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Strategic Buyout by MedTech OligopolyoligopolyA market structure dominated by a small number of firms, creating high barriers to entry.View full glossary entry | 35% | +120% | Competitive Positioning | A dominant medical technology giant struggling with its own premium lens pipeline acquires the company to capture its FDA-cleared post-operative adjustability patents. At a depressed valuation trading below book valuebook valueThe net asset value of a company calculated as total assets minus total liabilities.View full glossary entry, an acquisition would instantly eliminate redundant sales overhead and plug the technology into a global distribution network, triggering a massive buyout premium. |
| Next-Generation Material Materializes | 25% | +80% | Innovation And Product | The successful development of a next-generation polymer that eliminates the need for post-operative UV-blocking glasses would remove the primary patient compliance bottleneck. This breakthrough would dramatically simplify the clinical workflow, accelerating surgeon adoption and driving a vertical S-curve expansion in market share. |
Company Financial Analysis
RxSight Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
Recent financial trends show a sharp split between the company's hardware sales and its lens sales. Overall revenue has dropped, highlighted by a massive decline in the sales of their expensive laser machines due to tight clinic budgets. However, the sales of their specialized adjustable lenses continue to grow, which has pushed gross profit margins to an exceptional seventy-six percent. Despite these strong product profits, the company is still losing money overall because of high sales and administrative expenses. Experts agree that the company's future depends on whether it can transition from a high-growth machine seller to a steady lens provider. While some believe a recovery is just around the corner as inflation cools, others remain cautious, warning that overall profits will remain out of reach until management aggressively cuts back on overhead spending.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 134.5M | USD -38.9M | USD -19.3M |
| 2024 | USD 139.9M | USD -27.5M | USD -22.4M |
| 2023 | USD 89.1M | USD -48.6M | USD -46.4M |
| 2022 | USD 49M | USD -66.8M | USD -61.2M |
| 2021 | USD 22.6M | USD -48.7M | USD -46.6M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company's profit margins present a striking contrast. On one hand, its gross profit margin has expanded to an elite seventy-seven percent, proving that the individual adjustable lenses are incredibly profitable to make and carry immense pricing power. On the other hand, operating margins remain deeply negative because the company's fixed overhead costs are too high for its current sales volume. There is strong consensus that the high gross margin represents a coiled spring; once sales volume recovers or overhead costs are cut, overall profitability should improve rapidly. However, analysts clash on the timeline for this turnaround. Some believe that operating profits will return quickly as soon as the economic squeeze on seniors eases, while others argue that profitability will remain out of reach until management makes painful, deep cuts to its bloated sales force.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -48.2M | -35.8% | -29.0% |
| 2024 | USD -36.9M | -26.3% | -19.6% |
| 2023 | USD -50.1M | -56.2% | -54.6% |
| 2022 | USD -63.3M | -129.2% | -136.2% |
| 2021 | USD -52.8M | -233.6% | -215.5% |
Balance sheet and leverage
The company's balance sheet is its strongest shield, described by many as an absolute financial fortress. With a massive cash reserve, virtually zero debt, and a current ratio over ten, the company is completely safe from immediate financial distress or rising interest rates. This financial safety net means they do not need to borrow expensive money or issue new, dilutive stock to survive. There is high consensus that this pristine balance sheet provides excellent protection for investors, essentially setting a floor under the stock price. However, a key point of disagreement is how quickly this cash will be used up. Cautious observers warn that the cash pile will slowly shrink if the company continues to lose money on operations, while optimistic views believe the cash provides more than enough time to find a buyer or wait out the economic storm.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 11M | USD 228.1M | USD 8.9M net cash | 10.95x |
| 2024 | USD 12.3M | USD 237.2M | USD 4.4M net cash | 11.36x |
| 2023 | USD 3M | USD 127.2M | USD 6.7M net cash | 8.06x |
| 2022 | USD 45M | USD 105.8M | USD 33.2M net debt | 7.81x |
| 2021 | USD 44.9M | USD 159.3M | USD 20.6M net debt | 15.92x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company operates a highly efficient, capital-light business model, meaning it does not need to spend heavily on building factories or buying physical equipment. Its internal capital expenditures are very low, as the heavy lifting of research and development is largely complete. Instead, the real spending is concentrated in sales, marketing, and clinical support to encourage clinics to adopt their technology. Analysts agree that this low-capex setup is a major advantage in today's high-interest-rate environment because it protects cash flow. However, opinions differ on whether the current high spending on sales and marketing is necessary. Some believe this aggressive spending is vital to defend their market share against giant competitors, while others argue it is a wasteful use of cash during a economic slowdown and should be scaled back immediately to preserve the company's financial safety.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 3.8M | USD 38.5M |
| 2024 | USD 5.4M | USD 34.4M |
| 2023 | USD 4.8M | USD 29.1M |
| 2022 | USD 2.4M | USD 26M |
| 2021 | USD 1.9M | USD 24.5M |
Quarterly Forecast Scenarios
RxSight Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $4.9368 | $5.6895 | $7.0125 | $736.09 | |
| $4.5419 | $6.0919 | $8.0644 | $724.14 | |
| $4.3148 | $6.5119 | $8.8708 | $713.57 | |
| $4.7462 | $7.19 | $9.3144 | $723.38 | |
| $4.2716 | $7.9072 | $10.43 | $716.61 | |
| $4.058 | $8.6324 | $11.27 | $738.34 | |
| $4.1392 | $9.39 | $12.96 | $746.91 | |
| $4.3462 | $9.8541 | $14.03 | $771.93 | |
| $4.3462 | $10.51 | $15.72 | $782.73 | |
| $4.6069 | $11.25 | $16.97 | $807.31 | |
| $3.9159 | $12.25 | $19.52 | $822.72 | |
| $4.0725 | $13.09 | $21.47 | $846.10 | |
| $4.1947 | $13.85 | $23.64 | $852.53 | |
| $4.4044 | $14.65 | $26.47 | $882.91 | |
| $4.7568 | $15.65 | $29.12 | $900.46 | |
| $4.6617 | $16.69 | $30.58 | $922.67 | |
| $4.615 | $17.45 | $33.02 | $935.91 | |
| $5.1688 | $18.56 | $34.67 | $952.30 | |
| $4.8587 | $19.40 | $36.75 | $976.28 | |
| $4.9559 | $20.36 | $38.58 | $1,002 |
Research Provenance
References & Context
This RxSight consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2020-12-31–2026-01-01, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).